- 166studies in the library match, of 29,380
- 62name it in the title
- 2021–2026years published
- 158peer-reviewed articles
The query: title or abstract mentions "donanemab", "Kisunla" or "LY3002813", matched case-insensitively against each record's title and abstract (its summary field) in alzhub's library of 29,380 study records, as of 2026-11-08. Every count on this page comes from that match. The matched list as JSON.
Donanemab is a monoclonal antibody that targets a modified form of amyloid-beta found in established plaques. It is given by infusion, and in its trials treatment was stopped once a scan showed the plaques had been cleared.
As with lecanemab, the debate in the literature is about the size of the clinical benefit and the rate of ARIA (brain swelling or small bleeds). The counts below show how many papers address each.
This page describes what published research in alzhub's library reports. It is not medical advice and does not apply to any one person: a doctor who knows the person's history is the only one who can say what a result or a treatment means for them.
What the studies report, in their own words
Whole sentences copied from the abstract or key findings of the highest-scoring matched studies, chosen because they mention the subject and give a figure. 8 of the 166 matched records are quoted; each links to its study page and from there to the paper.
“Results At 6, 12, and 18 months, AP clearance was achieved in 37.9%, 70.0%, and 76.8%, respectively, of donanemab-treated participants versus 1.6%, 24.6%, and 43.1% of aducanumab-treated participants (P < 0.001).”
“Results Across 3030 total participants (placebo-controlled trials: 999 placebo participants, 984 donanemab participants; open-label addendum: 1047 donanemab participants), mean (SD) age was approximately 73.7 (6.0) years and 1684 participants (55.6%) were female.”
“There was a slowing of overall tau levels accumulation as well as relatively reduced functional and cognitive decline noted on the Integrated Alzheimer’s Disease Rating Scale by 32% in the Donanemab arm.”
“Greater than 90% of patients had positive treatment-emergent antidrug antibodies with donanemab.”
“The change from baseline in the iADRS score at 76 weeks was -6.86 with donanemab and -10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P = 0.04).”
“Donanemab modestly reduced cognitive decline compared to placebo: ADAS-Cog13 (MD, -1.86), CDR-SB (MD, -0.36), MMSE (MD, 0.64), and iADRS (MD, 3.19), with similar effects across tau subgroups.”
“Results Analyses included 1582 participants, including 766 treated with donanemab and 816 with placebo.”
“Donanemab-mediated slowing of disease progression occurred across baseline tau PET and plasma P-tau217 levels.”
What kind of evidence it is
By study design
| Design (as recorded) | Studies |
|---|---|
| Systematic review or meta-analysis | 18 |
| Randomised controlled trial | 1 |
| Other clinical trial | 22 |
| Cohort or longitudinal study | 7 |
| Other recorded design | 13 |
| No design recorded | 105 |
The design is the one named in alzhub's record for the study; a record with none is counted as "no design recorded".
By year
| Year | Studies | Share |
|---|---|---|
| 2026 | 42 | |
| 2025 | 72 | |
| 2024 | 24 | |
| 2023 | 12 | |
| 2022 | 11 | |
| 2021 | 5 | |
| 2020 | 0 | |
| 2019 | 0 | |
| 2018 | 0 | |
| 2017 | 0 |
Other counts within the matched set
| Peer-reviewed articles | 158 |
| Marked open access in the record | 75 |
| Rated "high" evidence strength in alzhub's summary | 39 |
| Rated "moderate" evidence strength in alzhub's summary | 20 |
| Rated "low" evidence strength in alzhub's summary | 105 |
| No evidence-strength rating | 2 |
| Records stating a participant count | 30 |
| Median participants (those records) | 1,021 |
| Largest participant count | 63,124 |
Within the 166 matched studies
| Studies… | Count | Rule |
|---|---|---|
| …that also discuss ARIA | 83 | the abstract also contains "ARIA" or "amyloid-related imaging abnormalities" |
| …that also mention TRAILBLAZER-ALZ, the trial programme | 27 | the abstract also contains "TRAILBLAZER" |
| …that also mention tau | 53 | the abstract also contains "tau" |
The 10 highest-scoring matched studies
Title matches first, then by alzhub's usefulness score, which rates a study's design, journal, evidence and recency, not whether its result is good news.
- Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3
- TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease
- Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials
- Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials
- Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial
- Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis
- Comparative efficacy, tolerability, and acceptability of aducanumab, lecanemab, and donanemab with repetitive transcranial magnetic stimulation on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis
- Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging
- Donanemab in Early Alzheimer's Disease
- Efficacy and APOE ε4-stratified risk of donanemab in Alzheimer's disease: A systematic review and meta-analysis of randomized clinical trials
Systematic reviews and meta-analyses in the set
18 of the matched records are recorded as a systematic review, meta-analysis or umbrella review; the highest-scoring not already listed above:
- Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis
- Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease: A systematic review and meta-analysis
- Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis
- Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness
- Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer's disease
Newest matched studies
- When Is Amyloid Really Cleared? Substantial Discordance Between Centiloid Quantitation and Visual Reads of Amyloid PET after Amyloid-Targeting Therapy
- Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab
- Drug-Drug Interaction Signals Between Anti-Amyloid-β Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis
- [Antibody therapy in Alzheimer's disease]
- Terapia anti β-amiloide y enfermedad cerebrovascular: nuevos retos para la neurología vascular
Journals with the most matched studies
| Journal | Studies |
|---|---|
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 7 |
| The journal of prevention of Alzheimer's disease | 6 |
| Zenodo (CERN European Organization for Nuclear Research) | 6 |
| Alzheimer s & Dementia | 5 |
| International journal of molecular sciences | 5 |
Questions
- What is donanemab?
- A monoclonal antibody against a form of amyloid-beta found in plaques, given by intravenous infusion, approved in the United States for early symptomatic Alzheimer's disease with confirmed amyloid. Its brand name is Kisunla.
- How is donanemab different from lecanemab?
- Both clear amyloid plaques, but they bind different forms of the protein, and donanemab's trials stopped dosing once plaques were cleared on a scan while lecanemab was given continuously. The papers listed below are the place to read how each trial measured its result.
- How many studies on donanemab (kisunla) does alzhub hold?
- 166 of the 29,380 study records in alzhub's library match the query "title or abstract mentions "donanemab", "Kisunla" or "LY3002813""; 62 of them name it in the title. Counted from the records when this page was built.
- What kinds of study are they?
- 18 systematic review or meta-analysis, 1 randomised controlled trial, 22 other clinical trials, 7 cohort or longitudinal studys; 105 record no design.
- What is the most recent study in the set?
- "When Is Amyloid Really Cleared? Substantial Discordance Between Centiloid Quantitation and Visual Reads of Amyloid PET after Amyloid-Targeting Therapy" (medRxiv, 2026), the newest by publication date among the matched records.
- Which journals publish most on it?
- Alzheimer's & dementia : the journal of the Alzheimer's Association (7); The journal of prevention of Alzheimer's disease (6); Zenodo (CERN European Organization for Nuclear Research) (6), counted across the matched records.
Read on
- Anti-amyloid antibodies: what the trials showedThe pivotal trial results and ARIA rates from each FDA label.
- Lecanemab and donanemab: do they work?A short answer page on both drugs.
- Lecanemab (Leqembi)The other approved antibody, on the same basis.
- ARIA: brain swelling and bleedsThe side effect both drugs share.